Affinivax, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2014-06-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.affinivax.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator
Phase 1
Completed
- Conditions
- Healthy VolunteersPneumococcal Disease
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Affinivax, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04525599
- Locations
- 🇺🇸
Dermatology Trial Associates, Bryant, Arkansas, United States
🇺🇸The Childrens Clinic, Jonesboro, Arkansas, United States
🇺🇸Emmaus Research Center, Inc, Anaheim, California, United States
Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Affinivax, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04265911
- Locations
- 🇯🇵
JP81001, Fukuoka, Japan
News
No news found